Navigation Links
Nanomedical Diagnostics Agile R100 Graphene Biosensor Characterizes Difficult-to-Study MYC Oncoprotein for Cancer Research
Date:8/7/2018

Nanomedical Diagnostics, leading manufacturer of graphene biosensors that accelerate pharmaceutical and biotherapeutics development, announces a new publication titled, “Synthetic Molecules for Disruption of the Myc Protein-Protein Interface” in the Elsevier journal Bioorganic & Medicinal Chemistry. The paper prominently features use of Agile R100, described as a “field-effect transistor (Bio-FET) platform,” to produce a new lead compound of significantly increased in vivo stability and solubility.

MYC is a prominent regulator gene that is a recognized actor in cancer initiation and maintenance, and thus a promising target for anti-cancer drugs. An intrinsically disordered protein, MYC can bind nonspecifically to and aggregate on dextran surfaces, making small molecule interaction studies for this “undruggable target” difficult to perform using traditional platforms. Agile R100 biosensors employ graphene surfaces that reduce nonspecific binding and enable direct binding measurements of challenging proteins such as MYC.

The paper describes the development of a screening platform incorporating Agile R100 as part of a blind structure-activity-relationship (SAR) study. “Our first attempts to characterize the interactions of MYC by surface plasmon resonance (SPR) gave us too high of a background due to non-specific interactions of the protein with the chip surface,” says Dr. Nicholas Jacob, lead author of the study. “In contrast, Agile R100’s graphene surface proved significantly less prone to these nonspecific interactions, and we were able to achieve a higher signal-to-noise ratio. The system allowed us to measure affinities for small molecule interactions with MYC in a label-free manner where other standard methods had failed.”

In the study, binding data from Agile R100 correlated well with data from in vivo microtumor formation inhibition assays using chicken embryo fibroblasts (CEF), as opposed to SPR data, which did not. The publication goes on to reference additional advantages of Agile R100: The system has a much lower limit of detection than SPR or isothermal calorimetry (ITC), and its site-specific functionalization decreased aggregation on the chip which further reduced nonspecific noise.

Agile R100 is a novel optics-free binding assay platform for the kinetic characterization of biomolecular interactions. As a graphene biosensor, Agile R100 monitors changes in electrical conductivity to gain sensitive label-free measurements, enabling real-time quantitative analysis of difficult-to-study molecules. “Agile R100 uses a novel electrical sensing mechanism that enables researchers to characterize difficult, disordered targets with less time and resources,” says Nanomedical Diagnostics CEO, Ross Bundy. “This is the first step towards understanding the biological pathways of historically undruggable targets like MYC, unlocking new opportunities for future cancer therapies.”

About Nanomedical Diagnostics

Nanomedical Diagnostics (“Nanomed”) is a life science company based in San Diego, CA. Nanomed has developed a breakthrough electrical assay based on proprietary Field Effect Biosensing (FEB) technology that delivers sensitive label-free kinetic characterization of biomolecular interactions for accelerated drug discovery. As the world’s leading developer and manufacturer of next-generation graphene biosensors, Nanomed’s mission is to transform the healthcare industry with innovative new products that enable cutting-edge life science research, drug discovery applications, and portable diagnostic and health monitoring platforms.

Read the full story at https://www.prweb.com/releases/nanomedical_diagnostics_agile_r100_graphene_biosensor_characterizes_difficult_to_study_myc_oncoprotein_for_cancer_research/prweb15675304.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology news :

1. Shared Medical Resources, LLC files suit against Histologics, LLC, Womens Health Laboratories and Avero Diagnostics for Willful Patent Infringement
2. OncoPlex Diagnostics Announces the Addition of the Androgen Receptor Protein to Their Quantitative Breast Cancer Proteomic Panel
3. Kalorama Report: Sizable Number of Acquisitions and Joint Ventures in Molecular Diagnostics
4. MicroRNA: An Insight to miRNA-based microarrays, diagnostics and therapeutics Overview, Cambridge Healthtech Advisors
5. handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities
6. Molecular Diagnostics - Global Market Size, Strategy and Forecasts - 2015 to 2019
7. Force Diagnostics and higi Partner to Provide Innovative Services to Life Insurance Industry:
8. Singulex and Thermo Fisher Scientific Enter into License and Supply Agreement to bring Next Generation Immunodiagnostics to Sepsis and SIRS Diagnostics
9. Heart Health Innovator Boston Heart Diagnostics Joins American College of Lifestyle Medicine Corporate Roundtable
10. Green photon beams more agile than optical tweezers
11. Global Cancer Biomarkers Market 2012-2016 with Agilent Technologies Inc., Gen-Probe Inc. and Astellas Pharma US Inc. Dominating
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2019)... ... July 26, 2019 , ... Worldwide ... Helius Medical Technologies CEO Phil Deschamps to discuss their potential new treatment option ... is a neurotech company in the medical device industry that's focused on ...
(Date:7/23/2019)... ... ... Personalized Stem Cells, Inc (“PSC”), a human adipose-derived stem cell company, has ... own adipose-derived stem cells to treat their osteoarthritis. The first clinical trial, expected to ... , This is the first of several planned clinical trials which will ...
(Date:7/19/2019)... ... July 19, 2019 , ... ... Amorphous and Crystalline States – Insights from Synchrotron X-ray Pair Distribution (SXPDF) Studies”. ... along with Chris Benmore of Argonne National Laboratory and Gabriel de Araujo of ...
Breaking Biology News(10 mins):
(Date:8/4/2019)... (PRWEB) , ... August 02, 2019 , ... Cirtec Medical ... invasive devices, today announced that it has begun construction on a 30,000 sq. ft. ... 15 miles from San Jose. , The facility, which is expected to be ...
(Date:7/19/2019)... Calif. (PRWEB) , ... July 18, 2019 , ... ... also known as “Ravi Everest,” will be joining forces with California-based charity Coalition ... held from July 20-22nd. Coalition Duchenne raises awareness and funding for Duchenne muscular ...
(Date:7/9/2019)... MOINES, Iowa (PRWEB) , ... July 08, 2019 , ... ... Des Moines, Iowa, the National Corn Growers Association (NCGA) announced the winners ... technology to improve a product or process using field corn to produce biobased materials. ...
(Date:6/18/2019)... ... June 18, 2019 , ... Personalized Stem Cells, Inc (“PSC”), a ... the FDA for use of a person’s own adipose-derived stem cells to treat their ... the knee. This IND is the first of several planned clinical trials which ...
Breaking Biology Technology: